Forte Biosciences, Inc.

FBRXNASDAQBeobachtung

US$76.99

+0.03 % today

COMPANY DATA

Sector: HealthcareIndustry: BiotechnologyCountry: USCEO: Paul A. WagnerEmployees: 23Market cap: 1.6 BIPO: 13/04/2017Web: www.fortebiorx.com

Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in…

PRICE HISTORY

26/08/25+583.7 %26/08/26

1D

+0 %

1W

+0.1 %

1M

+0.6 %

6M

+170.7 %

YTD

+182.3 %

1Y

+583.7 %

2Y

+813.2 %

5Y

-89.1 %

10Y

–

EARNINGS

Next earnings date

13/11/2026 (in 79 days)

Volatility around earnings

~-24% stronger price swings than usual

SCORES

Valuation

Valued significantly cheaper than its own historical average.

Why this value? Details with Pro only.

Trend

Clear uptrend.

Why this value? Details with Pro only.

Quality

Average balance sheet quality.

Why this value? Details with Pro only.

Dividend

Not enough data yet for an assessment.

Growth

Strong expected growth at a fair price.

Why this value? Details with Pro only.

Insider

Insiders are buying significantly more shares than they sell.

Why this value? Details with Pro only.

Earnings

Roughly meets expectations.

Why this value? Details with Pro only.

Revisions

More downgrades than upgrades from analysts recently.

Why this value? Details with Pro only.

Sentiment

Not enough data yet for an assessment.

Short Pressure

Very low short volume ratio, no selling pressure visible.

Why this value? Details with Pro only.

Register for free

Unlock all 9 scores

4 credits free on registration
Access to virtual portfolios and watchlist
No credit card, no payment details needed
No subscription, no minimum term
Our own servers in Germany, no US cloud

Create account →

Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 26/08/2026.

ASK THE AGENTS ABOUT FBRX

ANALYST ASSESSMENT

PRICE TARGET LOW

US$77.00

CONSENSUS

US$77.00

MEDIAN

US$77.00

PRICE TARGET HIGH

US$77.00

0

STRONG BUY

3

BUY

4

HOLD

0

SELL

0

STRONG SELL

7

TOTAL · Hold

DATE	ANALYST FIRM	RATING	ACTION
28/07/2026	Barclays	Overweight → Equal Weight	downgrade
17/11/2025	Chardan Capital	Buy	maintain
15/08/2025	Chardan Capital	Buy	maintain
24/06/2025	Chardan Capital	Buy	maintain
01/04/2025	Chardan Capital	Buy	maintain
04/12/2024	Chardan Capital	Buy	maintain
15/11/2024	Chardan Capital	Buy	maintain
19/08/2024	Chardan Capital	Buy	maintain

METRICS

P/E

-16.77

P/B

9.96

EV/EBITDA

-17.71

RETURN ON EQUITY

-12.7 %

NET MARGIN

0 %

DEBT/EQUITY

0

DIVIDEND YIELD

0 %

AS OF

30/06/2026

FREE FLOAT & LIQUIDITY

FREE FLOAT

87.1 %

FLOAT SHARES

17,852,834

AVG. DAILY VOLUME (30D)

2,102,371

INSIDER TRANSACTIONS (SEC)

DATE	INSIDER	ROLE	TRANSACTION	SHARES	PRICE	PLAN TYPE
06/07/2026	Riley Antony A	Officer	Option exercise	375	–	Spontaneous
06/07/2026	Riley Antony A	Officer	Tax settlement	134	21.32	Spontaneous
06/07/2026	Wagner Paul A.	Officer	Option exercise	1,250	–	Spontaneous
06/07/2026	Wagner Paul A.	Officer	Tax settlement	98	21.32	Spontaneous

ATTENTION

Price since yesterday: +0.0%

Search (Google Trends)

28/0731/0704/08

INSTITUTIONAL HOLDERS

FUND / INSTITUTION	SHARES	CHANGE	AS OF
Jain Global LLC	0	-15,597	30/06/2026
MARSHALL WACE, LLP	0	-150,307	30/06/2026
Engineers Gate Manager LP	0	-16,427	30/06/2026
SIMPLEX TRADING, LLC	0	-2,312	30/06/2026
683 Capital Management, LLC	0	-20,000	30/06/2026

Page 1 / 3

STOCK SPLITS

DATE	RATIO
28/08/2024	1:25
16/06/2020	1:15

Not investment advice. Past performance is not an indicator of future results.